Early Bird Registration
End Date: Jun 30, 2025
Sessions
Aug 05, 2025 | 09:00 AM GMT

2nd Webinar on Pharmaceutical Chemistry

Sessions

This track delves into cutting-edge formulation techniques, particularly leveraging nanotechnology to enhance drug solubility, stability, and targeted delivery. It focuses on the creation of smart delivery systems for efficient therapeutic outcomes.

  • Nanoparticles and liposomes for targeted delivery
  • Controlled-release and sustained-release formulations
  • Enhancing solubility and bioavailability of poorly soluble drugs

Emphasizing the molecular basis of drug action, this track covers the rational design and synthesis of therapeutic agents. It also explores structure-activity relationships (SAR) and optimization strategies for drug leads.

  • Structure-based drug design and QSAR
  • Ligand-receptor interactions and docking studies
  • Lead optimization and synthesis of analogs

Covering the full drug development pipeline, this track discusses the transition from basic research to clinical application. It includes screening, validation, and translational research efforts.

  • Target identification and validation
  • High-throughput and virtual screening methods
  • Translational challenges and preclinical studies

This track highlights state-of-the-art analytical tools used in quality control and regulatory compliance. It ensures drug safety through precise identification and quantification techniques.

  • Chromatographic techniques (HPLC, GC)
  • Spectroscopic methods (UV, NMR, IR)
  • Stability studies and method validation

Focusing on biologically derived drugs, this track discusses advances in biotechnology for producing vaccines, proteins, and gene therapies. It also examines regulatory and manufacturing challenges.

  • Recombinant protein production and purification
  • Monoclonal antibodies and biosimilars
  • Gene therapy and personalized biologics

Promoting sustainability in drug manufacturing, this track addresses eco-friendly chemical processes. It supports waste reduction, renewable resources, and safe chemical alternatives.

  • Green solvents and catalysts
  • Waste minimization in synthesis processes
  • Energy-efficient manufacturing techniques

This track emphasizes the ethical and scientific aspects of human studies in drug development. It includes study design, data collection, and regulatory considerations.

  • Phases I-IV of clinical trials
  • Patient recruitment and informed consent
  • Real-world evidence and post-market surveillance

Highlighting digital transformation, this track explores how AI and robotics streamline pharmaceutical R&D and clinical operations. These technologies help accelerate timelines and reduce costs.

  • AI in target prediction and drug repurposing
  • Automation in synthesis and high-throughput screening
  • Machine learning in clinical data analysis

Focused on compliance and documentation, this track covers the regulations ensuring product safety and efficacy. It also discusses international harmonization and audit readiness.

Good Manufacturing Practices (GMP)

Regulatory submission and approval processes (e.g., FDA, EMA)

Quality control and risk management systems

This track explores how drugs move through and affect the body, guiding dosage regimen design and therapeutic monitoring. It forms the scientific basis for efficacy and safety.

  • ADME processes and modeling
  • Dose-response relationships
  • Therapeutic drug monitoring and bioavailability

Focusing on affordable alternatives to branded drugs, this track discusses formulation, bioequivalence, and legal barriers in generic drug manufacturing and approval.

  • Abbreviated New Drug Application (ANDA) process
  • Bioequivalence and therapeutic interchangeability
  • Patent cliffs and litigation issues

Analyzing evolving trends, this track explores innovation, investment, and future directions in pharmaceutical sciences. It emphasizes digitalization, globalization, and collaboration.

  • Emerging markets and investment opportunities
  • Pharma-tech convergence and innovation hubs
  • Strategic partnerships and digital health integration